Results of a study investigating epcoritamab combined with lenalidomide and rituximab for treatment of relapsed follicular lymphoma.
Home / Resource Library / Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma